PDX Pharmaceuticals, LLC, has an office in Lake Oswego, Oregon, and a laboratory on the 13th floor of the OHSU’s Center for Health and Healing in Portland, Oregon. The company utilizes state of the art equipment at the Biomedical Engineering Department, core facilities, and animal facilities at OHSU.
We specialize in the development of chemically modified nanomaterials into drugs. These materials hold great promise for improving healthcare outcomes and greatly reducing cost. We are a leader in the field as a developer of such compounds (with over 40 peer-reviewed publications and 3 journal covers on applications of functionalized nanomaterials). In addition to nanomaterial development, we specialize in the development of animal models of cancer, kidney disease, and toxic metal exposure, which are necessary for the in vivo evaluation of our nanomaterials. Our company’s strength is in nanomaterial research and expertise that will lead to novel pharmaceutical products.
Wassana Yantasee, PhD, MBA, serves as the company’s President and CEO. She is an associate professor in Biomedical Engineering at OHSU and an Oregon Nanomedicine Signature Researcher. She has over 15 years of experience working with mesoporous silica and its biointerfaces. She has served as the PI for many NIH grants and contracts, has reviewed for several study sections of NIH, and others (DOE, DOD, and French National Research Agency, Marie Curie COFUND) and served on the editorial board of nanotechnology and cancer related journals.
Worapol Ngamcherdtrakul, PhD, is a senior Scientist. The focus of his PhD dissertation was to develop a mesoporous silica nanoparticle into a carrier for siRNA delivery to treat breast cancer. At PDX Pharma, he leads the development and optimization of nanoparticle platform to deliver drug, siRNA, and vaccine for several applications. He is the contact PI of PDX Pharm’s ongoing SBIR grants from the National Institute of Health.
Members of Yantasee lab at the department of Biomedical Engineering at Oregon Health and Science University.
PDX Pharmaceuticals has been in close collaboration with OHSU for the development of a siRNA-nanoparticle platform for breast cancer therapies under the fast-track phase I/II SBIR contract award from NCI. The OHSU team consists of an internationally renowned cancer genomics researcher, Prof. Joe Gray, PhD, and an siRNA-screening expert, Zhi Hu, PhD.
Multiple experts serve as consultants to PDX Pharmaceuticals (Table 1). They include breast cancer oncologist, Shiuh-Wen Luoh, MD, PhD, Phase I cancer clinical trial program lead at OHSU, Matthew Taylor, MD, Battelle Distinguished Inventor and synthetic chemist, Glen Fryxell, PhD, and a partner at Battelle Ventures, Tracy Warren, MBA.
Table 1. Advisory Panel of PDX Pharmaceuticals
|Gordon Mills, MD, Ph.D.||Professor and Director of precision oncology for the OHSU Knight Cancer Institute||Clinical precision oncology|
|Tracy Warren, MBA||Head of Life Sciences program/Battelle Ventures||Venture capital investment, commercialization of life sciences products|
|Matthew Taylor, MD||Lead of Phase I clinical trial/KCI of OHSU||Clinical trial phase I protocols including IRB, enrollment, treatment, and efficacy and safety monitoring procedures|
|Shiuh-Wen Luoh, MD, Ph.D.||Oncologist/OHSU and VA hospital||Standard treatment regimens for HER2+ breast cancer (dosing, efficacy, adverse effects)|
|Glen E Fryxell, Ph.D.||Battelle distinguished inventor||Expert in mesoporous silica synthesis and surface modifications with >120 publications and >6000 citations|
|Jorgen Kjems, Ph.D.||Prof. and Chair of iNANO/University of Aarhus||Chemical modification of siRNAs|
|Jeremy Heidel, Ph.D.||President/Informulate||Chemistry, Manufacturing, and Controls (CMC) of nanoparticles and siRNA formulation|
|Shawn Zinnen, Ph.D.||CEO/MBC Pharma||Key person in 4 IND filings with the FDA. Inventor of Sirna Therapeutic Inc.’s Herzyme, an anti-Her-2 targeted ribozyme, which was evaluated in human breast cancer trials|
|Jennifer Lockridge, Ph.D.||President/Lockridge Pharma Consulting||Expert in IND-enabling toxicity studies and project management of many oligonucleotide-IND programs.|
|Gregory Hardee, Ph.D.||Principal/Oligo Development||Pharmaceutical Research and Development, Drug delivery research.|